In addition to blockage of the SHH signaling pathway, ATO downregulates Notch signaling by decreasing the levels of Notch1 and Hes1 proteins having an inhibitory effect on GBM cancer stem-like cells in vitro and in vivo [244]. Here, NOTCH1 is linked to glioblastoma.